BioNTech SE (BNTX) AI Stock Analysis

Compare

4,583 Followers

Top Page

BioNTech SE

(NASDAQ:BNTX)

Rating:61Neutral

Price Target:

$119.00

▲(9.69%Upside)

BioNTech's strong balance sheet and positive technical momentum are offset by profitability challenges and financial losses highlighted in the earnings call. Strategic investments in oncology could drive future growth, but current financial risks weigh on the overall score.

Positive Factors

Financial Agreements

BioNTech will receive a $1.5B upfront payment and is eligible for up to $7.6B in milestone payments from Bristol Myers, enhancing financial stability.

Market Potential

The collaboration could lead to more combinatory options, expanding BNT327's market potential by addressing more indications.

Strategic Partnerships

The strategic partnership with Bristol Myers for BNT327 is reminiscent of those with Pfizer for COMIRNATY, potentially providing competitive advantages.

Negative Factors

Competitive Position

BioNTech is considered to be solidly in second position in the race, behind ivonescimab.

Risks and Challenges

Risks include negative data for various BioNTech products, including BNT327.

BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$26.08B

Dividend YieldN/A

Average Volume (3M)1.18M

Price to Earnings (P/E)―

Beta (1Y)0.89

Revenue Growth0.58%

EPS Growth-764.64%

CountryUS

Employees6,772

SectorHealthcare

Sector Strength42

IndustryBiotechnology

Share Statistics

EPS (TTM)-1.98

Shares Outstanding240,392,620

10 Day Avg. Volume1,542,003

30 Day Avg. Volume1,177,845

Financial Highlights & Ratios

PEG Ratio0.79

Price to Book (P/B)1.09

Price to Sales (P/S)0.00

P/FCF Ratio-100.16

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$139.91

Price Target Upside28.96% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

BioNTech SE Business Overview & Revenue Model

Company DescriptionBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

How the Company Makes MoneyBioNTech SE generates revenue through the development and commercialization of its mRNA-based therapies and vaccines. A significant portion of its income is derived from its collaboration with Pfizer, particularly from the sales of the COVID-19 vaccine, which has been distributed globally. The company also engages in strategic partnerships and licensing agreements with other pharmaceutical firms to enhance its development pipeline and expand its market reach. Additionally, BioNTech earns revenue through research grants and milestone payments associated with the progress of its clinical trials and product developments.

BioNTech SE Earnings Call Summary

Earnings Call Date:May 05, 2025

(Q1-2025)

% Change Since: 3.38%|

Next Earnings Date:Aug 04, 2025

Earnings Call Sentiment Neutral

The earnings call reflects a company that is making significant progress in its oncology programs and maintaining a strong financial position, despite experiencing decreased revenue and a higher net loss. The strategic investments in developing new therapies and preparing for future product launches are promising, but the financial losses and settlement expenses are notable challenges.

Q1-2025 Updates

Positive Updates

Advancements in Oncology Programs

BioNTech presented new clinical data for their bispecific immunomodulator BNT327 and mRNA cancer immunotherapies, showing potential to establish new standards of care in oncology. They are advancing towards commercialization with the first BLA submission for BNT323 planned by the end of 2025.

COVID-19 Vaccine Developments

BioNTech is preparing for a variant-adapted COVID-19 vaccine rollout and maintains a strong financial position to support these developments.

Strong Financial Position

Despite a net loss, BioNTech ended the quarter with €15.9 billion in total cash plus security investments, indicating robust financial health.

Negative Updates

Decreased Revenue and Increased Net Loss

BioNTech reported total revenues of approximately €183 million for Q1 2025, a slight decrease from €188 million in Q1 2024. The net loss for the first quarter of 2025 was €416 million, compared to a net loss of €315 million in the prior-year period.

High R&D and Settlement Costs

R&D expenses increased to €526 million, driven by late-stage clinical studies. Additionally, BioNTech faced significant settlement costs with NIH and the University of Pennsylvania, totaling approximately US$1.2 billion.

Company Guidance

In BioNTech's first quarter 2025 earnings call, the company provided guidance on several key metrics. They reported total revenues of approximately €183 million for the quarter, primarily from COVID-19 vaccine sales, compared to €188 million in the first quarter of 2024, reflecting expected seasonality. BioNTech's research and development expenses reached €526 million, up from €508 million in the prior-year period, driven by the advancement of late-stage clinical studies, including those for BNT327. Selling, general, and administrative expenses were €121 million, down from €133 million due to reduced external services. The company recorded a net loss of €416 million, compared to a €315 million loss in the same period last year, with a basic and diluted loss per share of €1.73 versus €1.31 previously. BioNTech ended the quarter with a strong cash position of €15.9 billion, despite significant outflows related to acquisitions and settlements. For the full year, BioNTech reaffirmed its 2025 financial guidance, projecting revenues between €1.7 billion and €2.2 billion, R&D expenses from €2.6 billion to €2.8 billion, SG&A expenses between €650 million and €750 million, and capital expenditures ranging from €250 million to €350 million.

BioNTech SE Financial Statement Overview

Summary

BioNTech SE's financial performance shows mixed results. While the balance sheet is strong with a low debt-to-equity ratio and high equity ratio, income and cash flow metrics have been volatile. Recent revenue and profit margin declines, combined with fluctuating cash flows, indicate potential areas for improvement.

Income Statement

Positive

BioNTech SE has experienced significant volatility in its revenue and profitability margins. The gross profit margin has generally been strong, averaging 80% during peak years, but has recently decreased. Net profit margin has also shown volatility, with recent negative figures after previous years of profitability. The revenue growth rate has been inconsistent, with a notable decline in recent years following a peak period.

Balance Sheet

Positive

The balance sheet of BioNTech SE is robust, with a strong equity ratio averaging around 85% over the years, indicating solid financial stability. The company has maintained a low debt-to-equity ratio, reflecting prudent financial management. However, the return on equity has been volatile due to fluctuating net income, indicating potential concerns in sustained profitability.

Cash Flow

Neutral

BioNTech SE's cash flow statement reveals fluctuating free cash flow, with recent negative figures following a period of strong positive cash flow. The operating cash flow to net income ratio has also varied significantly, pointing to inconsistencies in cash generation relative to reported profits. This variability poses a risk to cash flow stability.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
2.75B	3.82B	17.31B	18.98B	482.32M
	Gross Profit
2.21B	3.22B	12.78B	15.12B	-222.04M
	EBIT
-1.31B	690.40M	12.64B	15.28B	-82.42M
	EBITDA
-367.10M	1.09B	12.86B	15.73B	-97.89M
	Net Income Common Stockholders
-665.30M	930.30M	9.43B	10.29B	15.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
16.78B	16.55B	14.06B	2.07B	1.35B
	Total Assets
22.53B	23.01B	23.28B	15.83B	2.32B
	Total Debt
254.20M	219.10M	212.20M	301.50M	240.19M
	Net Debt
-9.51B	-11.44B	-13.66B	-1.39B	-970.02M
	Total Liabilities
3.12B	2.76B	3.22B	3.94B	946.77M
	Stockholders Equity
19.41B	20.25B	20.06B	11.89B	1.37B
Cash Flow		Free Cash Flow
-244.60M	4.67B	13.21B	735.70M	-98.92M
	Operating Cash Flow
207.70M	5.37B	13.58B	889.70M	-13.47M
	Investing Cash Flow
-2.08B	-6.95B	-35.30M	-566.10M	-144.85M
	Financing Cash Flow
-45.90M	-778.60M	-1.42B	94.20M	894.73M

BioNTech SE Technical Analysis

Technical Analysis Sentiment

Positive

Last Price108.49

Price Trends

50DMA

99.13

Positive

100DMA

105.55

Positive

200DMA

108.32

Positive

Market Momentum

MACD

2.95

Negative

RSI

57.16

Neutral

STOCH

55.87

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Positive. The current price of 108.49 is above the 20-day moving average (MA) of 100.44, above the 50-day MA of 99.13, and above the 200-day MA of 108.32, indicating a bullish trend. The MACD of 2.95 indicates Negative momentum. The RSI at 57.16 is Neutral, neither overbought nor oversold. The STOCH value of 55.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTX.

BioNTech SE Risk Analysis

BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the “Legal & Regulatory” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 1 New Risks

Q4, 2024

BioNTech SE Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMAB	82 Outperform	$13.60B	12.46	22.69%	―	25.11%	46.46%
ARGX	70 Outperform	$35.95B	42.18	17.33%	―	78.01%	―
ALNY	64 Neutral	$39.22B	―	-414.62%	―	17.21%	21.16%
BNTX	61 Neutral	$26.08B	―	-3.87%	―	0.58%	-764.64%
SWTX	54 Neutral	$3.53B	―	-51.57%	―	730.42%	31.63%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
MRNA	48 Neutral	$10.62B	―	-29.34%	―	-38.25%	44.29%

* Healthcare Sector Average

Performance Comparison

BNTX

BioNTech SE

108.49

10.51

10.73%

ALNY

Alnylam Pharma

300.83

147.36

96.02%

ARGX

Argenx Se

585.93

206.63

54.48%

GMAB

Genmab

22.20

-5.72

-20.49%

MRNA

Moderna

27.46

-121.13

-81.52%

SWTX

Springworks Therapeutics

46.80

6.83

17.09%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.